| Revenue growth | Standalone Q3 revenue grew 12% YoY; consolidated revenue rose 22% YoY. |
|---|---|
| Margins | Standalone EBITDA margin expanded significantly from 16% to 25% YoY. |
| Demand visibility | Strong Poultry demand; Animal segment recovery expected in Q4 via tenders. |
| Management confidence | Confident, highlighting operational discipline and capacity expansion benefits. |
Growth
Standalone Q3 revenue rose 12% to ₹703.5M; EBITDA grew 72% with margins expanding from 16% to 25%.
Outlook
Commencing PPR orders in February 2026; capacity doubled via new fill-finish facility capitalization to support future exports.
Risks
Animal Healthcare segment declined 38% in Q3 due to delayed government immunization programs and tender-based revenue dependence.
Earnings Call filed with NSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,167.20
- Market cap
- ₹1,844 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.5×Sector 47.3×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences Annual General Meeting
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Other Announcement
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.